CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer
China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...
Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an...
Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186),...
China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...
The National Health Commission (NHC) has released the “Somatic Cell Clinical Research Guidelines (draft proposal)”...
China-based Shunxi Holding Group Co. Ltd has entered into a licensing deal with Australia-based firm...
Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), has announced the acquisition of a land...
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG), emerging from a merger deal in...
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed...
China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...
Biosyngen Pte Ltd, a cell and gene therapy (CGT) biotech with operations in Singapore and...
Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell...
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...
China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing...
Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more...
New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David...
China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...
China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has...